ArticleResearch square2025
Bradycardia Risk Associated with Intravenous Dexmedetomidine: A Retrospective Study of Risk Factors and Clinical Outcomes in Critically Ill Patients (BRAID).
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
5 authors.
Funding
Abstract
Background: Dexmedetomidine is a selective α2-adrenergic agonist commonly used for sedation in intensive care units (ICUs). While effective, it is associated with cardiovascular side effects, particularly bradycardia that may limit its use. Concerns about bradycardia-related complications often influence clinical decision-making regarding dexmedetomidine dosing and monitoring, yet the true clinical significance of this side effect remains unclear. This study aimed to identify risk factors for dexmedetomidineassociated bradycardia and evaluate its impact on clinical outcomes. Methods: We conducted a retrospective cohort study involving adult patients who were mechanically ventilated and received dexmedetomidine for sedation across 12 ICUs in 4 hospitals under one hospital system. Bradycardia was defined as a heart rate below 60 beats per minute within 24 hours after dexmedetomidine administration. Multivariable logistic regression was employed to identify independent risk factors and assess the association between bradycardia and clinical outcomes, including inpatient mortality. Results: Among 5,106 patients, 1,143 (22.4%) developed bradycardia. Independent risk factors for bradycardia included moderate/severe liver disease (OR 1.87, 95% CI 1.42-2.47), dementia (OR 1.67, 95% CI 1.21-2.31), cerebrovascular disease (OR 1.32, 95% CI 1.15-1.51), and cancer (OR 1.25, 95% CI 1.06-1.47). Lower risk of bradycardia included congestive heart failure (OR 0.71, 95% CI 0.63-0.80) and myocardial infarction (OR 0.73, 95% CI 0.63-0.85). Crude mortality rates were similar between groups (11.4% vs. 10.2%, p = 0.297), and after adjustment for age and illness severity, bradycardia was not independently associated with hospital mortality (adjusted OR 0.99, 95% CI 0.79-1.23, p = 0.915). Patients with bradycardia had shorter ICU length of stay compared to those without bradycardia (10.4 ± 10.1 vs. 10.8 ± 10.6 days, p = 0.012). A sensitivity analysis adjusting for minimum heart rate before dexmedetomidine initiation and using a stricter bradycardia definition of heart rate less than 50 bpm, resulted in similar findings. Conclusions: Dexmedetomidine-associated bradycardia occurs in approximately one-quarter of ICU patients at out institution. Specific comorbidities significantly influence the risk of developing bradycardia, but dexmedetomidine-associated bradycardia itself may not associated with worse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.